Literature DB >> 15656928

Epidemiology, pathophysiology, and treatment of Barrett's esophagus: reducing mortality from esophageal adenocarcinoma.

Richard E Sampliner1.   

Abstract

The definition of BE has evolved over time. BE is the key premalignant lesion for developing EAC. The epidemiology and pathophysiology of BE is outlined, and risk factors for BE and EAC are reviewed. GERD plays a crucial role in the pathophysiology and the clinical identification of BE. Endoscopy with biopsy is the best tool for diagnosing and surveying patients with BE. Detection of early neoplasia is the present approach to reduce EAC mortality. Novel technology should assist in the early detection of dysplasia to enable targeted therapy. Effective chemopreventive strategies may reduce the risk of progression to EAC.

Entities:  

Mesh：

Year:  2005        PMID： 15656928     DOI： 10.1016/j.mcna.2004.08.008

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN： 0025-7125            Impact factor:   5.456


  9 in total

1.  Computer-assisted analysis of abrasive transepithelial brush biopsies increases the effectiveness of esophageal screening: a multicenter prospective clinical trial by the EndoCDx Collaborative Group.

Authors:  J F Johanson; J Frakes; D Eisen
Journal:  Dig Dis Sci       Date:  2010-12-04       Impact factor: 3.199

2.  Genetic variants of FOXP1 and FOXF1 are associated with the susceptibility of oesophageal adenocarcinoma in Chinese population.

Authors:  Jie Zhang; Jiebin Chen; Tianheng Ma; Huimin Guo; Bin Yang
Journal:  J Genet       Date:  2018-03       Impact factor: 1.166

3.  Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Katerina Dvorak; George S Watts; Lois Ramsey; Hana Holubec; Claire M Payne; Carol Bernstein; Gareth J Jenkins; Richard E Sampliner; Anil Prasad; Harinder S Garewal; Harris Bernstein
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

4.  Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study.

Authors:  Zoe R Edelstein; Mary P Bronner; Sheldon N Rosen; Thomas L Vaughan
Journal:  Am J Gastroenterol       Date:  2009-03-24       Impact factor: 10.864

5.  Transepithelial leak in Barrett's esophagus.

Authors:  J M Mullin; M C Valenzano; S Trembeth; P D Allegretti; J J Verrecchio; J D Schmidt; V Jain; J B Meddings; G Mercogliano; J J Thornton
Journal:  Dig Dis Sci       Date:  2006-11-14       Impact factor: 3.487

6.  Association between obesity and Barrett's esophagus in a Japanese population: a hospital-based, cross-sectional study.

Authors:  Jiro Watari; Kazutoshi Hori; Fumihiko Toyoshima; Noriko Kamiya; Takahisa Yamasaki; Takuya Okugawa; Haruki Asano; Zhao Liang Li; Takashi Kondo; Hisatomo Ikehara; Jun Sakurai; Toshihiko Tomita; Tadayuki Oshima; Hirokazu Fukui; Hiroto Miwa
Journal:  BMC Gastroenterol       Date:  2013-09-26       Impact factor: 3.067

7.  Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.

Authors:  Hyo Song Kim; Seung Eun Lee; Yoon Sung Bae; Dae Joon Kim; Chang-Geol Lee; Jin Hur; Hyunsoo Chung; Jun Chul Park; Da Hyun Jung; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee; Hye Ryun Kim; Yong Wha Moon; Joo Hang Kim; Young Mog Shim; Susan S Jewell; Hyunki Kim; Yoon-La Choi; Byoung Chul Cho
Journal:  Oncotarget       Date:  2015-02-10

8.  Total diet, individual meals, and their association with gastroesophageal reflux disease.

Authors:  Mehranghiz Ebrahimi-Mameghani; Siamak Sabour; Manouchehr Khoshbaten; Seyed Rafi Arefhosseini; Maryam Saghafi-Asl
Journal:  Health Promot Perspect       Date:  2017-06-14

9.  Insulin/Insulin-Like Growth Factor-1 Pathway in Barrett's Carcinogenesis.

Authors:  K B Greer; A Kresak; B Bednarchik; D Dawson; L Li; A Chak; J Willis
Journal:  Clin Transl Gastroenterol       Date:  2013-03-07       Impact factor: 4.488
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.